Human Pathology
Volume 34, Issue 1 , Pages 80-88 , January 2003

Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin

,Accepted 18 September 2002.

References 

  1. Toker C. Trabecular carcinoma of the skin. Arch Dermatol. 1972;105:107–110
  2. Tang C, Toker C. Trabecular carcinoma of the skin: An ultrastructural study. Cancer. 1978;42:2311–2321
  3. Savage P, Constenla D, Fisher C, et al.  The natural history and management of Merkel cell carcinoma of the skin: A review of 22 patients treated at the Royal Marsden Hospital. Clin Oncol (R Coll Radiol). 1997;9:164–167
  4. Skelton HG, Smith KJ, Hitchcock CL, et al.  Merkel cell carcinoma: Analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol. 1997;37:734–739
  5. Shaw JH, Rumball E. Merkel cell tumour: Clinical behaviour and treatment. Br J Surg. 1991;78:138–142
  6. Pitale M, Husain S, Sessions RB. An analysis of prognostic factors in cutaneous neuroendocrine carcinoma. Laryngoscope. 1992;102:244–249
  7. Tai PTH, Yu E, Tonita J, et al.  Merkel cell carcinoma of the skin. J Cutan Med Surg. 2000;4:186–195
  8. Medina-Franco H, Urist MM, Fiveash J, et al.  Multimodality treatment of Merkel cell carcinoma: Case series and literature review of 1924 cases. Ann Surg Oncol. 2001;8:204–208
  9. Murphy G, Docherty AJP. The matrix metalloproteinases and their inhibitors. Am J Resp Cell Mol Biol. 1992;7:120–125
  10. Stetler-Stevenson WG, Liotta LA, Kliener DE. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993;7:1434–1441
  11. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89:1260–1270
  12. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 1999;189:300–308
  13. Douglas DA, Shi YE, Sang QA. Computational sequence analysis of the tissue inhibitor of metalloproteinase family. J Prot Chem. 1997;16:237–255
  14. Liotta LA, Steeg PA, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell. 1991;64:327–336
  15. Davies B, Waxman J, Wasan H, et al.  Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 1993;53:5365–5369
  16. Muller D, Wolf C, Abecassis J, et al.  Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinoma. Cancer Res. 1993;53:165–169
  17. Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y, Manabe H. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int. 1997;47:461–469
  18. Hamdy F, Fadlon E, Cottam D, et al.  Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer. 1994;69:177–182
  19. Yamamoto H, Itoh F, Iku S, et al.  Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: Clinicopathologic and prognostic significance of matrylisin expression. J Clin Oncol. 2001;19:1118–1127
  20. Sier CF, Kubben FJGM, Ganesh S, et al.  Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer. 1996;74:413–417
  21. Michael M, Babic B, Khokha R, et al.  Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol. 1999;17:1802–1808
  22. Zeng SZ, Huang Y, Cohen AM, et al.  Prediction of colorectal cancer relapse and survival via tissue RNA levels of tissue metalloproteinase-9. J Clin Oncol. 1996;14:3133–3140
  23. Rosemurgy A, Harris J, Langleben A, et al.  Marimastat in patients with advanced pancreatic cancer: A dose-finding study. Am J Clin Oncol. 1999;22:247–252
  24. Jones L, Ghaneh P, Humphreys M, et al.  The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann N Y Acad Sci. 1999;880:288–307
  25. Yengpruksawan A, Coit DG, Thaler HT, et al.  Merkel cell carcinoma: Prognosis and management. Arch Surg. 1991;126:1514–1519
  26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  27. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187–202
  28. Birkedal-Hansen H, Moore WGI, Bodden MK, et al.  Matrix metalloproteinases: A review. Crit Rev Oral Biol Med. 1993;4:197–250
  29. Emonard H, Grimaud JA. Matrix metalloproteinases: A review. Cell Mol Biol. 1990;36:131–153
  30. Kubochi K. New direct assay method of type IV collagenase in tissue homogenate and biochemical role of collagenase against type I and type IV collagens to the invasion of stomach and lung cancer. Nippon Geka Gakkai Zasshi. 1990;91:174–183
  31. Kimura A. Localization of matrix metalloproteinases and their inhibitor in pulmonary carcinomas. J Juzen Med Soc. 1992;101:344–355
  32. Iwata H, Kobayashi S, Iwase H, et al.  The expression of MMPs and TIMPs in human breast cancer tissues and importance of their balance in cancer invasion and metastasis. Nippon Rinsho. 1995;53:1805–1810
  33. Murray GI, Duncan ME, O'Neil P, et al.  Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol. 1998;185:256–261
  34. Murray GI, Duncan ME, Arbuckle E, et al.  Matrix metalloproteinases and their inhibitors in gastric cancer. Gut. 1998;43:791–797
  35. Murray GI, Duncan ME, O'Neil P, et al.  Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 1996;14:461–462
  36. Ito T, Ito M, Shiozawa J, et al.  Expression of the MMP-1 in human pancreatic carcinoma: Relationship with prognostic factors. Mod Pathol. 1999;12:669–674
  37. Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg. 2000;87:1215–1221
  38. Chin JR, Murphy G, Werb Z. Stromelysin, a connective tissue degrading metallo-proteinase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. Biosynthesis, isolation, characterization and substrates. J Biol Chem. 1985;260:12367–12376
  39. Shima I, Sasaguri Y, Kusukawa J, et al.  Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behaviour of esophageal carcinoma. Cancer. 1992;70:2747–2753
  40. Tomita T. Matrix metalloproteinases and tissue inhibitors in thyroid C-cells and medullary thyroid carcinomas. Histopathology. 1997;31:150–156
  41. Tomita T, Iwata K. Gelatinases and inhibitors of gelatinases in pancreatic islets cell tumors. Mod Pathol. 1997;10:47–54
  42. Walsh NMG. Primary neuroendocrine (Merkel cell) carcinoma of the skin: Morphologic diversity and implications thereof. Hum Pathol. 2001;32:680–689

☆ Address correspondence and reprint requests to Professor Marco Santucci, Dipartimento di Patologia Umana ed Oncologia, Università degli Studi di Firenze, Viale Morgagni, 85 50134 Firenze, Italy.

PII: S0046-8177(03)00006-6

doi: 10.1053/hupa.2003.51

Human Pathology
Volume 34, Issue 1 , Pages 80-88 , January 2003

Article Tools

* Image Usage & Resolution